PwPepwise

Defensins (α/β)

Immune Support

a.k.a. HNP-1 · HBD-2 · etc.

Antimicrobial peptide family

Defensins are a family of small, naturally occurring antimicrobial peptides that form a critical part of the human immune system.

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
General protocol0.36–0.40 µg—IntravenousInjected directly into a vein.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Defensins are a family of small, naturally occurring antimicrobial peptides that form a critical part of the human immune system. Divided into two main subfamilies — alpha-defensins (found predominantly in neutrophils and intestinal Paneth cells) and beta-defensins (expressed mainly in epithelial tissues of the skin, gut, and respiratory tract) — these peptides serve as the body's frontline chemical defense against bacteria, fungi, and viruses3,7. Alpha-defensins such as HNP-1, HNP-2, and HNP-3 appear to directly kill a broad range of pathogens including bacteria, fungi, and herpes simplex virus in laboratory studies7, while beta-defensins such as hBD-2 and hBD-3 appear to recruit immune cells to sites of infection through interactions with the CCR6 receptor, linking innate and adaptive immunity5. In skin conditions such as atopic dermatitis, reduced levels of these protective peptides may contribute to increased susceptibility to bacterial infections4. Beyond direct antimicrobial activity, beta-defensins have been reported to activate dendritic cells and may play roles in anti-HIV defense10. Defensin-based therapeutics are actively being developed for oncology and infectious disease applications, with early-stage human trials currently underway1.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Defensins are cationic, cysteine-rich peptides of 18–45 amino acids characterized by a conserved tridisulfide bond framework that stabilizes their tertiary structure. Alpha-defensins adopt a triple-stranded beta-sheet conformation stabilized by three disulfide bonds in a 1–6, 2–4, 3–5 pairing pattern, while beta-defensins share a similar scaffold with a 1–5, 2–4, 3–6 connectivity3,7,18. The primary antimicrobial mechanism involves electrostatic interaction between the peptides' net positive charge and the negatively charged phospholipid head groups of microbial membranes, leading to membrane permeabilization and pathogen lysis7,12. The importance of net positive charge for biological activity is underscored by the observation that hBD-27, despite possessing the conserved beta-defensin disulfide scaffold, exhibits virtually no antimicrobial or cytotoxic activity attributable to its significantly lower positive charge compared to active family members18. Beyond direct membrane disruption, beta-defensins function as chemoattractants through high-affinity engagement of CCR6, a G-protein-coupled chemokine receptor expressed on immature dendritic cells and CCR6+ memory T cells5. Beta-defensin-induced CCR6 signaling proceeds through pertussis toxin-sensitive Gi proteins, mirroring the signaling of canonical chemokine ligands and enabling competitive displacement of the endogenous CCR6 ligand LARC5. Beta-defensin 2 additionally engages TLR-4 — a pattern recognition receptor classically activated by bacterial lipopolysaccharide — inducing costimulatory molecule upregulation and proinflammatory cytokine secretion in dendritic cells comparable to LPS stimulation, establishing defensins as endogenous ligands for innate immune signaling receptors10. Transcriptional regulation of beta-defensins is pathway-specific: hBD-2 induction by bacterial infection or IL-1α proceeds via NF-κB activation9, and in fungal infection models hBD-2 is synergistically regulated by both NF-κB and AP-1 pathways, while hBD-3 expression is entirely NF-κB-independent and relies exclusively on an EGFR/MAPK/AP-1 signaling axis15. Alpha-defensins circulate in plasma predominantly as biologically inactive proHNP precursor forms, with mature active HNPs representing a minor fraction; proHNPs are renally filtered and reabsorbed in proximal tubules, a pharmacokinetic consideration relevant to interpreting plasma defensin measurements in disease contexts13. In intestinal epithelium, hBD-1 is constitutively expressed while hBD-2 is inducibly expressed upon bacterial invasion or cytokine stimulation through NF-κB-dependent mechanisms, establishing a two-tier defense architecture combining baseline and inducible antimicrobial coverage9.

§04Evidence & efficacy

Evidence base
405Studies
143Human
10Animal

Defensins demonstrate broad-spectrum antimicrobial activity across multiple pathogen classes in preclinical and in vitro settings. Alpha-defensins HNP-1, HNP-2, and HNP-3 appear to kill bacteria including S. aureus, P. aeruginosa, and E. coli, eradicate the fungal pathogen C. neoformans, and inactivate herpes simplex virus type 1 in laboratory conditions7. Beta-defensin hBD-3 appears to demonstrate bactericidal activity against multidrug-resistant A. baumannii at lethal concentrations of 2–16 mg/L and against E. cloacae at 8 mg/L, though HNP-1 showed no detectable activity against any tested ESKAPE Gram-negative pathogen12. Recombinant hBD-1 and hBD-2 in combination may provide synergistic antibacterial activity, achieving up to 90% bacterial inhibition in vitro compared to approximately 50% for either peptide alone, with in vivo mouse studies reporting increased survival time and reduced bacterial burden in a Salmonella model11. Full-length HBD-1 through HBD-3 appear to exert antifungal activity against Candida albicans, with the fungal membrane identified as the primary site of action19. Alpha-defensins 1 and 2 have been reported to inhibit multiple HIV-1 isolates in vitro and may contribute to CD8 T cell-mediated antiviral activity10. In the oncology space, a defensin-based therapeutic is being evaluated as a combination partner with checkpoint inhibitors in solid tumors, with efficacy data emerging from active trials1.

§05Safety

The safety profile of exogenous defensin peptides in humans is an active area of clinical investigation, with formal human safety data currently emerging from early-phase trials. The sole registered human clinical trial of a defensin-based therapeutic (STI-7349) lists safety, tolerability, dose-limiting toxicities, and maximum tolerated dose determination as primary endpoints, with no safety results yet published1. In preclinical mouse models, recombinant hBD-1 and hBD-2 administered intraperitoneally appeared to reduce tissue damage and sepsis formation in infected livers compared to untreated infected controls, suggesting acceptable tolerability at therapeutic doses in that model11. In vitro hemolytic assessments indicate that hBD-27 demonstrated minimal cytotoxic or hemolytic activity, while hBD-2, hBD-3, and hBD-28 showed comparatively higher cytotoxicity in erythrocyte assays18. The combination of a defensin-based agent with PD-1/PD-L1 checkpoint inhibitors in the STI-7349 trial introduces potential immunotoxicity risks that the protocol is specifically designed to characterize1. Endogenous defensin levels are elevated in certain inflammatory and infectious states — including COVID-19 in pregnancy17 and atopic dermatitis-associated infection4 — providing context for their biological activity range, though these observations pertain to endogenous peptides rather than exogenous therapeutic administration.

§06History

The defensin field was formally established in 1985 when Ganz, Selsted, Lehrer, and colleagues isolated and characterized three small cationic peptide antibiotics — HNP-1, HNP-2, and HNP-3 — from human neutrophil azurophil granules, naming this class 'defensins' and demonstrating their broad-spectrum activity against bacteria, fungi, and herpes simplex virus7. This landmark discovery positioned defensins as central effectors of oxygen-independent neutrophil microbicidal mechanisms. Through the 1990s, beta-defensins were identified as distinct epithelial-expressed family members; the characterization of intestinal hBD-1 and inducible hBD-2 expression in gut epithelium expanded the defensin concept beyond hematopoietic cells into barrier tissues9. A paradigm shift occurred in 1999 when Yang, Oppenheim, and colleagues demonstrated that beta-defensins function as chemoattractants for CCR6-expressing dendritic cells and T cells, establishing these antimicrobial peptides as molecular bridges between innate and adaptive immunity5. The early 2000s saw rapid expansion: Ong et al. in 2002 demonstrated defensin deficiency as a mechanistic basis for S. aureus susceptibility in atopic dermatitis4, and Ganz's 2003 review consolidated the field's foundational knowledge3. Concurrently, alpha-defensins were identified as contributors to CD8 antiviral factor activity against HIV-1, and beta-defensin 2 was shown to engage TLR-410. The 2010s brought recognition that Paneth cells — the intestinal cells producing alpha-defensins — also serve as critical stem cell niche organizers6, broadening defensin biology beyond antimicrobial function. Therapeutic development has accelerated into the 2020s, with defensin-inspired oncology agents such as STI-7349 entering human clinical trials as immuno-oncology combination partners1.

§07References